Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women

Maturitas

Volumn 63, Issue 4, 2009, Pages 329-335

  Utian, Wulf ^a   Yu, Holly ^b   Bobula, Joel ^b   Mirkin, Sebastian ^b   Olivier, Sophie ^b   Pickar, James H ^b  

^a Rapid Medical Research   (United States)

^b PFIZER INC   (United States)

Author keywords

Bazedoxifene; Conjugated estrogens; Health related quality of life; Hot flushes; Postmenopausal; Sleep; Tissue selective estrogen complex (TSEC)

Indexed keywords

BAZEDOXIFENE; BAZEDOXIFENE PLUS CONJUGATED ESTROGEN; CONJUGATED ESTROGEN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AMENORRHEA; ARTICLE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; ENDOMETRIUM HYPERPLASIA; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; PATIENT SATISFACTION; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SLEEP DISORDER; TREATMENT RESPONSE;

ADULT; AGED; DOUBLE-BLIND METHOD; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; INDOLES; LINEAR MODELS; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SLEEP;

EID: 68149132588     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.06.006     Document Type: Article

References (46)

1. Utian W. The true clincal features of postmenopause and oöphorectomy, and their response to oestrogen therapy. S Afr Med J 46 (1972) 732-737
2. Dennerstein L., Dudley E.C., Hopper J.L., Guthrie J.R., and Burger H.G. A prospective population-based study of menopausal symptoms. Obstet Gynecol 96 (2000) 351-358
3. Utian W.H. Quality of life (QOL) in menopause. Maturitas 57 (2007) 100-102
4. Feldman B.M., Voda A., and Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health 8 (1985) 261-268
5. Rödström K., Bengtsson C., Lissner L., Milsom I., Sundh V., and Björkelund C. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause 9 (2002) 156-161
6. Woods N.F., and Mitchell E.S. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 118 (2005) 14-24
7. Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol 29 (1994) 319-336
8. Utian W.H., Janata J.W., Kingsberg S.A., Schluchter M., and Hamilton J.C. The Utian Quality of Life (UQOL) Scale: development and validation of an instrument to quantify quality of life through and beyond menopause. Menopause 9 (2002) 402-410
9. Utian W.H. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 3 (2005) 47
10. Freedman R.R., and Roehrs T.A. Effects of REM sleep and ambient temperature on hot flash-induced sleep disturbance. Menopause 13 (2006) 576-583
11. Freedman R.R., and Roehrs T.A. Sleep disturbance in menopause. Menopause 14 (2007) 826-829
12. Cauley J.A., Seeley D.G., Ensrud K., Ettinger B., Black D., and Cummings S.R. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 122 (1995) 9-16
13. Utian W.H., Shoupe D., Bachmann G., Pinkerton J.V., and Pickar J.H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 75 (2001) 1065-1079
14. Erlik Y., Tataryn I.V., Meldrum D.R., Lomax P., Bajorek J.G., and Judd H.L. Association of waking episodes with menopausal hot flushes. JAMA 245 (1981) 1741-1744
15. Beresford S.A., Weiss N.S., Voigt L.F., and McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349 (1997) 458-461
16. Voigt L.F., Weiss N.S., Chu J., Daling J.R., McKnight B., and van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 338 (1991) 274-277
17. Pitkin J., Smetnik V.P., Vadasz P., Mustonen M., Salminen K., and Ylikangas S. Continuous combined hormone replacement therapy relieves climacteric symptoms and improves health-related quality of life in early postmenopausal women. Menopause Int 13 (2007) 116-123
18. Archer D.F., and Pickar J.H. Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding. Obstet Gynecol 96 (2000) 899-905
19. Panay N., and Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 3 (1997) 159-171
20. Manonai J., Theppisai U., Suchartwatnachai C., Jetsawangsri T., and Chittacharoen A. Compliance with hormone replacement therapy in Thai women. Maturitas 44 (2003) 201-205
21. Wattanakumtornkul S., Chichareon S., Geater A., and Suwan K. Compliance with hormone replacement therapy at Songklanagarind Hospital. J Obstet Gynaecol Res 29 (2003) 380-387
22. Jordan V.C., Gapstur S., and Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 93 (2001) 1449-1457
23. Miller P.D., Chines A.A., Christiansen C., et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23 (2008) 525-535
24. Silverman S.L., Christiansen C., Genant H.K., et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 23 (2008) 1923-1934
25. Kharode Y., Bodine P.V., Miller C.P., Lyttle C.R., and Komm B.S. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 149 (2008) 6084-6091
26. Komm B.S. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci 15 (2008) 984-992
27. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women [published online ahead of print July 26, 2009]. Fertil Steril; doi:10.1016/j.fertnstert.2009.02.093.
28. Lobo RA, Pinkerton JV, Gass MLS, Dorin MH, Ronkin S, Pickar JH, Constantine G. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile [published online ahead of print July 26, 2009]. Fertil Steril; doi:10.1016/j.fertnstert.2009.03.113.
29. Kagan R., Gass M.L., Williams R.S., Olivier S., and Pickar J.H. SMART-3: effects of the tissue selective estrogen complex (TSEC) bazedoxifene (BZA) and conjugated estrogens (CE) on vulvar/vaginal atrophy (VVA) and sexual function in postmenopausal women [abstract S-4]. Menopause 14 (2007) 1081
30. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conguated estrogens as a menopausal therapy [published online ahead of print July 26, 2009]. Fertil Steril; doi:10.1016/j.fertnstert.2009.05.094.
31. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women [published online ahead of print July 26, 2009]. Fertil Steril; doi:10.1016/j.fertnstert.2009.05.093.
32. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens: a randomized, controlled trial [published online ahead of print June 10, 2009]. Menopause; doi:10.1097/gme.0b013e3181a7df0d.
33. Hlatky M.A., Boothroyd D., Vittinghoff E., Sharp P., and Whooley M.A. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 287 (2002) 591-597
34. Adler G., Young D., Galant R., Quinn L., Witchger M.S., and Maki K.C. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms. Gynecol Obstet Invest 59 (2005) 212-219
35. Mendoza N., Pison J.A., Fernandez M., Sanchez M.C., Malde J., and Miranda J.A. Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus. Maturitas 41 (2002) 289-298
36. Huber J., Palacios S., Berglund L., et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 109 (2002) 886-893
37. Allen R.P., Kosinski M., Hill-Zabala C.E., and Calloway M.O. Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep). Sleep Med 10 (2009) 531-539
38. Katz D.A., and McHorney C.A. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 51 (2002) 229-235
39. Hays R.D., Martin S.A., Sesti A.M., and Spritzer K.L. Psychometric properties of the Medical Outcomes Study Sleep Measure. Sleep Med 6 (2005) 41-44
40. Zollner Y.F., Acquadro C., and Schaefer M. Literature review of intruments to assess health-related quality of life during and after menopause. Qual Life Res 14 (2005) 309-327
41. Serrano D., Mariani L., Mora S., et al. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT. Maturitas 55 (2006) 69-75
42. Hilditch J.R., Lewis J., Peter A., et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 24 (1996) 161-175
43. Hill C.D., Fehnel S.E., Bobula J.D., Yu H., and McLeod L.D. Development and preliminary validation of the Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ). Menopause 14 (2007) 1047-1055
44. Bobula J.D. Vasomotor symptoms and quality of life (QoL) in postmenopausal women. Value Health 6 (2003) 707
45. Thurston R.C., Bromberger J.T., Joffe H., et al. Beyond frequency: who is most bothered by vasomotor symptoms?. Menopause 15 (2008) 841-847
46. Ohayon M.M. Severe hot flashes are associated with chronic insomnia. Arch Intern Med 166 (2006) 1262-1268